• No results found

OUR COMMITMENT TO INNOVATION. Company Presentation

N/A
N/A
Protected

Academic year: 2021

Share "OUR COMMITMENT TO INNOVATION. Company Presentation"

Copied!
40
0
0

Loading.... (view fulltext now)

Full text

(1)

Company Presentation

OUR

COMMITMENT

(2)

2

TABLE OF CONTENTS

(BY SECTION)

About us Who we are ▪ Founding ▪ Our Mission ▪ Innovation timeline What we do ▪ Addressing, transforming ▪ Our therapies and solutions ▪ Our business groups

▪ Technology innovation

How we do it

▪ Our people, workplace, & global presence ▪ Culture of quality

▪ Commitment to the community

(3)

ABOUT

(4)

4

Company Presentation | July 2019

MEDICAL TECHNOLOGY

IS WHAT WE DO.

IT’S WHAT WE’VE

ALWAYS DONE.

You may know us as the pacemaker company, the diabetes pump maker, or

(5)

Therapies to treat more than

70 conditions in the human body

Abdominal Aortic Aneurysm (AAA) • Atrial Fibrillation • Barrett’s Esophagus • Blood Pressure Basics • Bradycardia (Slow Heartbeat) • Breath Monitoring • Cancer Pain • Cervical Herniated Discs • Cervical Disc Degeneration • Chronic Pain • Colon Disease • Coronary Artery Disease (CAD) • Crohn’s Disease • Dysphagia (Difficulty Swallowing) • Dystonia • Ear Infections • Epilepsy • Essential Tremor • Fecal Incontinence • Gastroesophageal Reflux Disease (GERD) • Gastroparesis • GI Bleeding • Hearing Loss • Heart Failure • Heart Palpitations • Heart Valve Disease • Hernia • Hydrocephalus • Idiopathic Intracranial Hypertension • Lung Cancer • Normal Pressure Hydrocephalus • Obesity • Obsessive-Compulsive Disorder (OCD) • Overactive Bladder • Parkinson’s Disease • Peripheral Arterial Disease • Polyps • Pulmonary Valve Disease • Sacroiliac Joint Dysfunction • Scoliosis • Severe Spasticity • Sinus Infections • Spinal Fractures • Suspected Atrial Fibrillation • Tachycardia (Fast Heartbeat) • Thoracic Aortic Aneurysm (TAA) • Thyroid Conditions • Type 1 & Type 2 Diabetes • Unexplained Fainting • Unexplained Stroke • Urinary Retention

5

Company Presentation | July 2019

WE CREATE

INNOVATIONS

AT THE

THERAPEUTIC,

PROCEDURAL,

(6)

Ablation products • Aortic stent graft products • Balloon kyphoplasty • Biomaterials • Bone conductive hearing device • Brain monitoring • Capnography monitoring • Cardiac monitors • Cardiac resynchronization therapy (CRT) systems • Cardiopulmonary products • Cerebral/somatic oximetry • Continuous Glucose Monitoring system • Coronary stents • Cranial repair products • Deep brain stimulation system • Dialysis • Drug-coated balloons • Drug infusion systems • Electrosurgical products • Endoscopic ultrasound products • External defibrillators • Gastric electrical stimulation systems • Health informatics & monitoring • Heart valves replacement • Hernia repair • High-speed surgical drills & tools • Hysteroscopy systems • Image-guided surgery • Implantable cardiac defibrillator (ICD) systems • Infusion sets • Insulin pumps with continuous monitors • Laser ablation technology • Motility testing products • Nerve monitoring products • Pacing systems • Peripheral embolization products • Reflux testing products • Revascularization products • Sacral neuromodulation systems • Shunts • Smoke evacuation systems • Spine robotics • Support catheters • Surgical navigation systems • Surgical stapling • Therapy management software • Tumor management • Ultrasonic dissection • Ventricular assist devices (VAD) • Vertebroplasty • Vessel sealing • Wound closure

6

Company Presentation | July 2019

WE CREATE

INNOVATIONS

AT THE

THERAPEUTIC,

PROCEDURAL,

AND SYSTEM LEVEL

(7)

TOGETHER,

WE IMPROVE THE LIVES

OF PEOPLE

(8)

SUPPORTING THE

GLOBAL FIGHT

AGAINST

(9)

9

THE PANDEMIC BECAME A CATALYST FOR CHANGE

We are innovating in new ways and partnering with new companies to help aid the pandemic relief efforts through work such as:

▪ The development of personal protective equipment using 3-D scanners ▪ The creation of a new, simple, low-cost ventilator made in partnership

with the University of Minnesota, Boston Scientific, UnitedHealth Group and others, and more

CARING FOR COMMUNITIES

The Medtronic Foundation found ways to amplify our employees’ passion to help through:

$13M

2:1

*

*2:1 matching from June – March 2020

COMMITMENT TO COVID-19 RESPONSE EFFORTS

(10)

10

THE PANDEMIC BECAME A CATALYST FOR CHANGE

We are working with others to increase the global supply of ventilators by:

▪ Increasing our production of ventilators

▪ Publicly sharing the design specifications for our portable compact ventilator to allow others around the world to join the fight

Within the first week

of open sourcing the design specs of our portable compact ventilator

(11)

11

THE PANDEMIC BECAME A CATALYST FOR CHANGE

We are finding new ways to safely serve patients, by:

▪ Using existing remote patient monitoring devices in new ways

(12)

To learn more about our efforts, visit:

www.medtronic.com/covid19

THE ROAD TO RECOVERY

(13)

13

Company Presentation | July 2019

(14)

WHO

(15)

15

Company Presentation | July 2019

FOUNDED ON

INNOVATION AND

COLLABORATION

Since the late 1940s, we have been working with others to

alleviate pain, restore health, and extend life.

Our late co-founder and lifelong innovator, Earl Bakken, holding the world’s smallest

pacemaker today next to the world’s first

(16)

WRITTEN IN 1960, OUR MISSION

DRIVES EVERYTHING WE DO.

To contribute to human welfare by application of biomedical engineering in the research, design,

manufacture, and sale of instruments or appliances that alleviate pain, restore health, and extend life.

1

To direct our growth in the areas of biomedical engineering.

2

To strive without reserve for the greatest possible reliability and quality in our products.

3

To make a fair profit.

4

To recognize the personal worth of all employees.

5

To maintain good citizenship.

6

(17)

OUR RICH HISTORY OF INNOVATION

HOW WE’VE GROWN OVER THE YEARS

1960 1949 1977 1983 1999 2001 2002 2015 2017 MEDTRONIC IS FOUNDED 1957 1979 CREATED FIRST BATTERY-OPERATED, EXTERNAL PACEMAKER EXPANDED INTO NEURO-STIMULATION INTRODUCED PROSTHETIC HEART VALVE EXPANDED INTO SPINAL CARE INTRODUCED FIRST REMOTE MONITORING SYSTEM ACQUIRED COVIDIEN EXPANDED INTO DIABETES CARE ESTABLISHED THE MEDTRONIC FOUNDATION WROTE OUR MISSION INTRODUCED

THE WORLD’S SMALLEST PACEMAKER

AND THE

FIRST HYBRID

(18)

TWO-COLUMN CONTENT SLIDE

MEDICAL

TECHNOLOGY

HAS THE

POWER TO

CHANGE LIVES

(19)

“The future of healthcare requires new approaches and new forms of

innovation. Medtronic is stepping forward to put the full power of our technologies — and our people — to work with new partners, in new ways, and drive value across the healthcare ecosystem. Only through collaboration can we drive healthcare toward a

healthier, more efficient future.

— Medtronic Chief Executive Officer, Geoff Martha

(20)

WHAT

(21)

ADDRESS UNIVERSAL

HEALTHCARE CHALLENGES

Populations are aging Chronic diseases are rising Many payment and

delivery systems reward volume over value

Government policies and regulatory systems are impacting innovations and increasing time to market

21

(22)

22

Company Presentation | July 2019

COMMITTED TO HELPING

TRANSFORM HEALTHCARE

GLOBALIZATION THERAPY INNOVATION Introducing and delivering meaningful offerings at the therapeutic, procedural, and system level

Addressing the

inequities in healthcare access globally

ECONOMIC VALUE

Helping lead the creation of value-based

(23)

23

Company Presentation | July 2019

OUR THERAPIES AND

SOLUTIONS IMPROVE LIVES

More than 70 conditions in the human body are treated with our therapies, enabling us to address chronic

conditions and provide healthcare solutions

BRAIN

EAR, NOSE & THROAT HEART & VASCULAR AIRWAY & LUNG

(24)

24

WE OFFER THERAPIES AND SOLUTIONS

ACROSS OUR FOUR BUSINESS GROUPS

Company Presentation | July 2019

CARDIAC &

VASCULAR

GROUP

▪ Aortic, Peripheral and Venous ▪ Cardiac Ablation Solutions ▪ Cardiac Rhythm and Heart

Failure

▪ Coronary and Structural Heart

DIABETES

GROUP

Therapies and services for insulin dependent Type 1 and Type 2 patients

MINIMALLY

INVASIVE

THERAPIES

GROUP

▪ Renal Care Solutions

▪ Respiratory, Gastrointestinal and Informatics ▪ Surgical Innovations

RESTORATIVE

THERAPIES

GROUP

▪ Cranial and Spinal Technologies ▪ Neuromodulation

(25)

25

Company Presentation | July 2019

▪ Aortic, Peripheral and Venous ▪ Cardiac Ablation Solutions

▪ Cardiac Rhythm and Heart Failure ▪ Coronary and Structural Heart

CARDIAC &

VASCULAR

GROUP

Cardiac Cryoballoon

Catheter Transcatheter Heart Valves

Transcatheter Pacing System

(26)

26

Company Presentation | July 2019

Therapies and services for insulin dependent Type 1 and Type 2 patients

DIABETES

GROUP

Mobile Monitoring Tools Diagnostic CGM

(27)

27

Company Presentation | July 2019

▪ Renal Care Solutions

(28)

28

Company Presentation | July 2019

▪ Cranial and Spinal Technologies ▪ Neuromodulation

▪ Specialty Therapies

RESTORATIVE

THERAPIES

GROUP

Targeted Drug Delivery

Revascularization Devices

(29)

29

Company Presentation | July 2019

MEDTRONIC CONTINUES TO LEAD

IN TECHNOLOGY INNOVATION

Reveal LINQ™ ICM CoreValve™

TAVR Solitaire™ Revascularization

PillCam™ Capsule Endoscopy

Surgical Robotics System

Arctic Front Advance™ Cryoballoon

MiniMed™ 670G Insulin Pump System

Micra™ Wireless Pacing System Continuous Innovation

Enhancing the clinical outcomes and economic value of existing products

Invention

creating and developing new therapies that result in new markets

Disruption

Disruptive therapies in existing markets

StealthStation™ Surgical Navigation

Resolute ONYX™ Drug-eluting stent

VisiaAF™ ICD Signia™ Surgical

Stapling Intellis™ Implantable

Neurostimulator Azure™ Pacing

System

(30)

HOW

WE

(31)

31

Company Presentation | July 2019

OUR PEOPLE

Medtronic employee Amanda Miranda returned to work as a biomedical engineer after spending six years away to attend to her family. Through Careers 2.0 — a Medtronic hiring initiative for women in engineering that helps them return to the industry after personal time away — Miranda found a position that fits her skills and helps her feel like she’s making a difference.

90,000+

EMPLOYEES

And tremendous clinical expertise and investments*:

* Numbers are representative of this past year.

10,700+

SCIENTISTS & ENGINEERS

1,700+

CLINICAL PROFESSIONALS

▪ $2.3 billion in R&D investments

▪ $465+ million in clinical investments ▪ 4,400+ patents

▪ 350+ clinical trials

(32)

32

OUR WORKPLACE

Company Presentation | July 2019

Corporate Responsibility Magazine recognizes Medtronic on 100 Best Corporate Citizens List Wall Street Journal recognizes Medtronic as a “Best Run Company” in 2019 DiversityInc Recognizes Medtronic in Annual

“Top 50” list for the fourth year in a row Catalyst recognizes Medtronic as an organization that advances women in leadership roles Forbes Magazine named Medtronic one of “America’s Best Employers For New Grads” Fortune Magazine recognizes Medtronic as a diverse and inclusive company

(33)

33

Company Presentation | July 2019

OUR GLOBAL PRESENCE

Headquarter Locations

Medtronic Operational Headquarters

Minneapolis, Minnesota

Medtronic Principal Executive Office

Dublin, Ireland

AMERICAS

EUROPE, MIDDLE EAST, & AFRICA

ASIA PACIFIC GREATER CHINA REGIONS

4

ORGANIZED IN DISTRIBUTION SITES

19

MANUFACTURING SITES

74

COUNTRIES

150+

OPERATE IN

(34)

34

Company Presentation | July 2019

OUR COMMITMENT TO QUALITY

IS ROOTED IN PATIENT SAFETY

Ensuring reliable, effective, and safe products

Quality and reliability are the DNA of our company, making them cornerstones of the

Mission statement.

It informs the Medtronic business strategy in therapy innovation, globalization, and economic value, and guides global teams when

(35)

35

DRIVING A MINDSET OF EXCELLENCE

THROUGH A CULTURE OF QUALITY

Company Presentation | July 2019

FIVE BENEFITS OF

A CULTURE OF QUALITY

1. Greater patient health and safety

2. Accountable and empowered employees 3. Heightened credibility with partners

4. Innovative culture

5. Stronger cost efficiencies

“Building a culture of quality is the

greatest commitment we can make to our customers, clinicians, and patients,”

(36)

36

OUR COMMITMENT TO THE COMMUNITY

FY20 Company Presentation | July 2019

33% MEDTRONIC FOUNDATION GIVING ($34.2M) 54% CASH CONTRIBUTIONS ($56.4M) 10% PRODUCT DONATIONS ($10.2M) 4% EMPLOYEE VOLUNTEERISM ($4.3M)

$105

TOTAL: MILLION

(37)

37

FY20 Company Presentation | July 2019

Through progress and partnership we are reaching further than ever before to transform healthcare. This means helping our partners and providers improve quality and efficiency of care through medical technology and deep clinical expertise.

(38)
(39)

TWO-COLUMN CONTENT SLIDE

(40)

40

FY20 Company Presentation | July 2019

OUR LEADERS

Shaping healthcare’s future

CHRIS LEE

SVP and President, Asia Pacific Region

RICHARD E. KUNTZ, MD, MSC

SVP and Chief Medical and Scientific Officer

GEOFFREY S. MARTHA Chief Executive Officer OMAR ISHRAK Executive Chairman and Chairman of the Board NOEL COLÓN SVP and Chief Quality Officer JOHN LIDDICOAT, MD

EVP and President, Americas Region

MICHAEL J. COYLE

EVP and President, Cardiac and VascularGroup ALEX GU SVP and President, Greater China BRAD LERMAN SVP, General Counsel and Corporate Secretary KAREN L. PARKHILL

EVP and Chief Financial Officer

SEAN SALMON

EVP and President, Diabetes Group

ROB

TEN HOEDT

EVP and President, Europe, Middle East, and Africa Region

BRETT WALL

EVP and President, Restorative Therapies Group

CAROL A. SURFACE, PHD

SVP and Chief Human Resources Officer

BOB WHITE

EVP and President, Minimally Invasive Therapies Group MIKE WEINSTEIN SVP, Strategy LAURA MAURI, MD, MSC

References

Related documents